Helixgate

Helixgate

Uncategorized

Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next

Published

on

Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous swelling attacks. The biotech aims to have its …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist

Published

on

With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.

Continue Reading

Uncategorized

Hospital shootings steadily increased since 2000

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. I was charmed by this profile of tween life in America, both as a former tween girl and as a reporter. I laughed out loud at one tween asking her friend, the main subject of the story: “You’re still getting interviewed?”

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. I was charmed by this profile of tween life in America, both as a former tween girl and as a reporter. I laughed out loud at one tween asking her friend, the main subject of the story: “You’re still getting interviewed?”

Read the rest…

Read More

Continue Reading

Uncategorized

Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma

Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma

Published

on

Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases.

The buyout will add three medicines to Angelini’s portfolio: Firdapse for Lambert-Eaton myasthenic syndrome, Agamree …​ ​Read More

Continue Reading
Advertisement

Trending